Acumen reports Q2 EPS (34c), consensus (28c)

“Our team is highly focused on execution in 2024, and I’m very pleased with our progress in the first half of the year. We are actively enrolling subjects in our global Phase 2 ALTITUDE-AD study that we initiated this spring. We are highly encouraged by the level of interest from investigators and patients in sabirnetug’s mechanism of action which has led to enrollment progressing faster than our expectations,” said Daniel O’Connell, Chief Executive Officer of Acumen. “In addition to the progress with ALTITUDE-AD, we announced in July the initiation of a Phase 1 pharmacokinetic comparison study supporting subcutaneous administration of sabirnetug. Topline results from this healthy volunteer study are expected in the first quarter of 2025. With the momentum in our clinical program and sabirnetug’s distinct selectivity for toxic amyloid beta oligomers, we believe that we are positioned to deliver a potential next-generation treatment for early Alzheimer’s disease.”